GLYC News and Press, GlycoMimetics Inc. From 04/09/24

2024-04-09 16:59:07 ET Gainers: Tilray Brands ( TLRY ) +25% . Performant Financial Corporation ( PFMT ) +13% . Farmer Brothers Company ( FARM ) +5% . GlycoMimetics  ( GLYC ) +4% . PriceSmart ( PSMT ) +4% . Losers: SM...

2024-03-27 11:53:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips GlycoMimetics (NASDAQ: GLYC ) just reported results for the fourth quarter of 2023. GlycoMimetics reported earnings per share of -14 cents. This was above the analyst esti...

2024-03-27 10:27:07 ET GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Conference Call March 27, 2024 08:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer Bruce Johnson - Chief Commerc...

2024-03-27 07:08:21 ET More on GlycoMimetics GlycoMimetics Can Become A Game Changer In Blood Cancers GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real Seeking Alpha’s Quant Rating on GlycoMimetics Historical earnings data ...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 New Drug Application (NDA) for uproleselan to be submitted to the U.S. Food and Drug Administration (FDA) by end of 2024 if outcome of R/R AML pivotal ...

2024-03-26 13:44:30 ET More on GlycoMimetics GlycoMimetics Can Become A Game Changer In Blood Cancers GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real Seeking Alpha’s Quant Rating on GlycoMimetics Historical earnings data ...

2024-03-21 17:47:38 ET Summary GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor prognosis, especially for elderly patients, and the...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be ...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44 th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET. A live webcast of the panel presentation will...